AbbVie Inc. $ABBV Shares Sold by Polaris Capital Management LLC

Polaris Capital Management LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 7.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,944 shares of the company’s stock after selling 10,700 shares during the period. AbbVie comprises about 2.2% of Polaris Capital Management LLC’s portfolio, making the stock its 20th biggest position. Polaris Capital Management LLC’s holdings in AbbVie were worth $32,866,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie during the 2nd quarter worth $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter worth about $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV opened at $219.99 on Tuesday. The firm has a market cap of $388.80 billion, a price-to-earnings ratio of 166.66, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The firm’s fifty day moving average price is $226.75 and its 200 day moving average price is $215.76. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Evercore ISI boosted their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Citigroup cut their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a voluntary agreement with the Trump administration that includes a pledge to invest $100 billion in U.S. R&D and capital over the next decade and an exemption from tariffs and future pricing mandates — a regulatory win that reduces trade/tariff uncertainty and signals long‑term U.S. investment. AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
• Positive Sentiment: AbbVie is buying a Tempe, Arizona manufacturing facility from West Pharmaceutical Services and acquiring manufacturing/supply rights for the SmartDose 3.5mL on‑body delivery system — immediate capacity and device IP that support next‑generation injectable medicines and reduce supply risks. AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
• Positive Sentiment: AbbVie inked an exclusive licensing/development deal with RemeGen for RC148, a PD‑1/VEGF bispecific antibody, in a pact worth up to roughly $4.95–$5.6 billion in milestones — a meaningful oncology pipeline add that could drive long‑term upside if clinical development succeeds. AbbVie, RemeGen partner on experimental solid tumor treatment
• Neutral Sentiment: AbbVie joined other large drugmakers calling for the FDA to modernize post‑approval change rules — could improve manufacturing flexibility long‑term but timing and regulatory outcomes are uncertain. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: AbbVie reported completion of its ABBV‑932 bipolar depression Phase 2 trial — a development milestone investors will watch for data readouts, but clinical timing/outcomes remain the next catalysts. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion: What Investors Should Watch Next
• Negative Sentiment: As part of the U.S. agreement, AbbVie agreed to provide lower Medicaid prices (via TrumpRx) for a three‑year period — this pricing concession introduces near‑term revenue/margin risk and is the main downside investors are weighing against the tariff relief and investment commitments. Abbvie, US reach agreement to cut drug prices

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.